Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. The Glaucoma Energy Crisis: How Pyruvate Rescues Failing Eyes (And Why Your Fitness Level Matters)

    1일 전

    The Glaucoma Energy Crisis: How Pyruvate Rescues Failing Eyes (And Why Your Fitness Level Matters)

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/the-glaucoma-energy-crisis-how-pyruvate-rescues-failing-eyes-and-why-your-fitness-level-matters Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Demand-Driven Metabolism: Why 3g of Pyruvate Won’t “Rev Up” a Couch Potato Your cells are like a precisely-tuned factory, only cranking out ATP (the cellular “energy currency”) when there’s work to do. If you’re sedentary and not using extra energy, simply swallowing a few grams of pyruvate won’t flood cells with power. In fact, cells regulate their energy supply very tightly. High levels of ATP actually shut down key energy pathways: for example, abundant ATP inhibits the enzyme pyruvate dehydrogenase (PDH) and instead activates pyruvate carboxylase (). In plain terms, if the “battery” (ATP) is already full, the cell stops using fuel. Extra pyruvate then gets shunted into storage or recycled rather than magically generating a feeling of buzz. In short, cellular energy production is strictly demand-driven. Even if you load up on pyruvate, an inactive body won’t convert it to extra ATP unless it’s needed. Instead, the surplus pyruvate enters normal metabolic “overflow” routes, including: Gluconeogenesis (Glucose Synthesis): In the liver, pyruvate (often via lactate) can be converted back into glucose to maintain blood sugar levels. This involves carboxylating pyruvate to oxaloacetate and eventually making glucose (). It’s an energy-intensive process – the body won’t do it without reason. Lactate Cycle: Excess pyruvate in muscles can be turned to lactate, which is shuttled to the liver and made into glucose, recycling energy. This prevents a build-up of metabolic waste and helps maintain blood glucose in rest. Fat Synthesis (Minor Route): Only in situations of chronic, massive over-supply does pyruvate contribute to fat. Experimentally, adipose tissue barely converts pyruvate into fatty acids unless its concentration is extremely high (tens of mM) (). In practical terms, a 3 g supplement won’t flood your blood with enough pyruvate to trigger significant fat storage. Gastrointestinal Effects: Strong organic acids can upset the stomach if overdone. High supplemental doses (dozens of grams) are known to cause gas, bloating or diarrhea (). In most studies, moderate doses (a few grams) are well-tolerated, but any abrupt high-dose intake could irritate the gut. The bottom line: If your cells don’t need more ATP, extra pyruvate is either turned back into sugar (used later) or simply stored without giving you a noticeable energy boost. The body won’t just burn it for no reason, and at high doses one might just feel tummy trouble (). The Glaucoma Energy Crisis: A Localized Shortage in the Retina In glaucoma, the optic nerve – built from retinal ganglion cells (RGCs) – faces a unique energy bottleneck. RGCs are extreme energy hogs: they fire constantly, maintain big voltage differences, and transmit visual signals non-stop. In fact, the retina is physiologically the most energy-hungry tissue in the body () (). One review notes that “the retina is the highest oxygen-consuming organ in the human body” and inner retinal neurons (like RGCs) have “the highest metabolic rate of all central nervous tissue” (). Simply put, RGCs are like high-powered computers that never sleep. They need large ATP supplies just to keep their ion pumps running and signals flowing (). With age and g Support the show

    11분
  2. Photobiomodulation (670 nm) for Aging Retina: Lifespan Signals from Flies to Mammals

    1일 전

    Photobiomodulation (670 nm) for Aging Retina: Lifespan Signals from Flies to Mammals

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/photobiomodulation-670-nm-for-aging-retina-lifespan-signals-from-flies-to-mammals Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction As we age, eye cells gradually lose energy and function, partly because their mitochondria (the cell’s “batteries”) become weaker (). This is true in the retina – the light-sensitive tissue at the back of the eye – where dying mitochondria contribute to poorer vision and diseases like age-related macular degeneration (AMD). Photobiomodulation (PBM) is a gentle therapy that uses low-intensity red or near-infrared light (usually around 670 nm wavelength) to stimulate cells. Laboratory studies suggest that shining 670 nm light into the eye can recharge mitochondrial function, boosting energy (ATP) production and easing inflammation () (). In practical terms, this therapy is often done with LED lamps or lasers positioned near the eye for a few minutes each day. Early experiments – from simple flies to mice and small human trials – hint that PBM might improve retinal health and even aspects of whole-body aging. This article reviews how 670 nm light benefits photoreceptors and retinal ganglion cells, summarizes results in experimental models (including lifespan effects in insects), and discusses dosing, safety, and possible home use. Finally, we suggest future studies that combine vision tests with markers of mitochondrial health to see if this light can boost not just eyesight, but overall cellular “youth.” How near-infrared light boosts retinal cells Photobiomodulation at 670 nm targets mitochondria, the tiny structures inside cells that make most of our energy (ATP). In mitochondria, a key enzyme called cytochrome c oxidase absorbs red/near-infrared light, which helps it run more efficiently () (). In effect, 670 nm light raises the electrical membrane potential of mitochondria and lets them crank out more ATP () (). Studies show this extra energy relieves age-related decline: for example, one report found that a month of daily 670 nm light in old mice roughly corrected their low mitochondrial membrane potential and ATP levels (). In addition, energized mitochondria produce fewer harmful free radicals, so treated cells show less oxidative stress and inflammation () (). Photoreceptors (the retina’s light-sensing rods and cones) and retinal ganglion cells (RGCs, the nerves that carry visual signals to the brain) are high-energy cells packed with mitochondria. By boosting mitochondrial activity, 670 nm light helps these cells work more efficiently. Lab studies find that photobiomodulation can directly improve photoreceptor metabolism and survival. For instance, in a mouse model of light-induced retinal damage, 670 nm treatment greatly improved photoreceptor health: treated cells had stronger mitochondrial respiration and less stress-induced damage (). Likewise, in an optic-nerve injury model, 670 nm light preserved RGCs: treated rats showed a 3.4-fold increase in visual signal strength and 1.6 times more surviving RGCs, along with higher retinal ATP levels and antioxidant markers (). In summary, by dialing up mitochondrial efficiency in these retina cells, photobiomodulation can make aged or stressed eye cells behave more like young, healthy ones. Results from animal studies Researchers have tested 670 nm PBM in various aging and disease models with encouraging results. In aged mic Support the show

    13분
  3. What’s New in Glaucoma Research in April 2026? What Patients Should Know

    2일 전

    What’s New in Glaucoma Research in April 2026? What Patients Should Know

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/what-s-new-in-glaucoma-research-in-april-2026-what-patients-should-know Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: What’s New in Glaucoma Research in April 2026? What Patients Should Know Glaucoma is a group of eye diseases that slowly damage the optic nerve, often due to high pressure inside the eye. It’s sometimes called the “silent thief of sight,” because vision can go gradually without you noticing (). Worldwide, glaucoma is a leading cause of irreversible blindness – in fact it’s the second-most common cause of blindness globally (after cataracts) (). Researchers are always looking for new clues about how it works and how to catch or treat it earlier. In April 2026, several new studies made headlines. We explain them in plain language below. (For context, note that a January 2026 study found the enzyme GPX4 – glutathione peroxidase 4 – helps protect eye nerve cells from damage (). But that study is from January, not the April updates.) Tiny Blood Vessel Leaks and Glaucoma Damage What the study found: A new research report suggests that tiny leaks in tiny blood vessels in the eye may contribute to glaucoma damage. In simple terms, researchers observed that microscopic blood vessels in the retina (the back of the eye) can become slightly leaky. This leak could let fluid or blood components escape into parts of the eye where they shouldn’t be. Over time, such leaks might stress or damage the optic nerve fibers. (Think of it like very small blood vessel “drips” that harm delicate tissue nearby.) Why it matters: We usually think of glaucoma damage as due to pressure; this study hints that blood vessel health is also important. If true, it could open new treatment ideas (for example, medicines to strengthen those vessels or reduce leakage). It’s an unusual idea in glaucoma research, so it’s still early-stage. It reminds us that glaucoma might involve more than just simple pressure – the circulation in the eye may play a role. How it was studied: This kind of research is usually done in laboratory models (animals or cell/tissue tests), not yet in people. The study did tests on eye tissue (or possibly in animals) to look for leaks under a microscope. (Because it’s new and detailed work, it’s not a large human trial.) Patient impact now: Right now, this finding does not change how we treat glaucoma. It’s a clue in the lab. Patients should continue their usual pressure-lowering treatments. In the future, if this line of research pans out, doctors might test additives that protect those tiny vessels. Big-picture importance: On a scale of 1–10 (10 = game-changing, 1 = interesting but small), this gets about a 5/10. It’s intriguing because it suggests a new mechanism, but it’s still early. More research will be needed to know if vessel leaks are a major factor in most glaucoma cases or only a minor one. A Possible Nerve-Protecting Drug (WAY-100635) What the study found: Another April 2026 study looked at a drug called WAY-100635 (pronounced “way-ten-thousand-six-hundred-thirty-five”). This compound affects serotonin receptors in the brain, but researchers tested it to see if it could protect eye nerve cells. In lab tests, giving WAY-100635 seemed to shield retinal ganglion cells (the neurons that form the optic nerve) from damage caused by glaucoma-like stress. In other words, in their experiments, eyes Support the show

    9분
  4. A New Clue in Glaucoma: Leaky Blood Vessels May Damage Vision

    3일 전

    A New Clue in Glaucoma: Leaky Blood Vessels May Damage Vision

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/a-new-clue-in-glaucoma-leaky-blood-vessels-may-damage-vision Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: A New Clue in Glaucoma: Leaky Blood Vessels May Damage Vision Glaucoma is known as the “silent thief of sight,” slowly damaging the eye’s nerve cells and causing vision loss. Today new research hints at surprising factors that could help protect vision or even restore it. In April 2026, scientists reported several findings that may affect how we understand and treat glaucoma. These include a study linking leaky tiny blood vessels to nerve damage, a tested drug (WAY-100635) that helps keep nerve cells alive, and an artificial intelligence (AI) tool to catch glaucoma earlier. We’ll explain each in plain language, note how close they are to helping patients, and give each finding an importance rating (1–10) for the big picture. We’ll also briefly mention a January 2026 study on a protective enzyme (GPX4) from past news. Leaky Retinal Blood Vessels and Glaucoma (Importance: 6/10) One new idea is that damage to small retinal blood vessels might contribute to glaucoma. Normally, the tiny blood vessels in the retina have tight barriers that keep fluid and cells from leaking into the delicate nerve layer. But if this “blood-retinal barrier” breaks down, harmful substances or immune cells could slip through and hurt the retinal ganglion cells (RGCs) – the nerve cells lost in glaucoma. A recent lab study found evidence for this effect. In experiments on mice, researchers showed that removing certain immune cells (microglia) caused retinal vessels to become leaky after injury (). This leakiness allowed inflammation in the retina and actually reduced the ability of nerve cells to regrow their connections. In other words, when the blood vessels leaked, nerve repair was worse. The study highlighted that keeping the vessels sealed is important for nerve protection. It’s important to note this was early lab work (in mice) looking at injury models, not human trials. Still, it suggests that future glaucoma treatments might also aim to strengthen vessel barriers or control inflammation. Despite being only in the lab so far, this finding is interesting because it adds a new clue to what makes glaucoma worse. (Rating: about 6/10 – it’s an early discovery that opens new research ideas, but far from direct patient treatments.) A healthy blood-retinal barrier has long been known as critical in diabetes and retinal diseases (), and now it’s being studied in glaucoma too. Drug WAY-100635 Protects Nerve Cells (Importance: 7/10) Another April 2026 result came from a drug screen on retinal nerve cells. Scientists tested a series of compounds on human-like retinal ganglion cells grown in the lab. They found that WAY-100635, a drug originally studied in the brain, helped these glaucoma-vulnerable nerve cells survive and function better. Specifically, the drug boosted the cells’ energy factories (mitochondria) and reduced their suicide signals. The study () (published 02 April 2026 in Communications Medicine) used both cell cultures and mouse models of optic nerve injury and glaucoma. When mice were given WAY-100635, their retinal ganglion cells were better protected after damage. Importantly, treated mice kept more of their vision: tests showed their eyes could still send signals to the brain with much less loss. In simple terms, WAY-100635 acted like a “neuroprotecto Support the show

    11분

  5. 4일 전

    April 2026 Glaucoma Trial Launches: A Global Landscape Review

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/april-2026-glaucoma-trial-launches-a-global-landscape-review Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: April 2026 Glaucoma Trial Launches: A Global Landscape Review Glaucoma is a leading cause of irreversible blindness worldwide. An estimated 76 million people had glaucoma in 2020, with that number projected to exceed 111 million by 2040 (). Most glaucoma treatments work by lowering intraocular pressure (IOP), the fluid pressure inside the eye, but new therapies aim to protect nerve cells and preserve vision. In April 2026 dozens of new glaucoma clinical trials officially began in registries around the world (ClinicalTrials.gov, EU CTR, ISRCTN, ANZCTR, CTRI, ChiCTR, WHO ICTRP). These trials span a range of intervention types – including new medications, implants and devices, surgical procedures, and digital health tools – and together paint a picture of current research priorities. New Trials by Modality The April 2026 trials can be grouped by their main intervention modality: Drug (Medication) Trials: The largest category remains medication studies. These include novel eye drops that lower IOP (for example new prostaglandin analogues or rho-kinase inhibitors) as well as systemic drugs being repurposed. Recent years have seen interest in metabolic and neuroprotective agents – for example, trials of oral diabetes drugs (GLP-1 agonists) or vitamins that may protect retinal nerve cells () (). Some trials involve sustained-release formulations (tiny implants that slowly release IOP-lowering drugs). For instance, one ongoing Phase II study is testing a tiny biodegradable implant (“TimoD”) that slowly releases the glaucoma drug timolol (). Overall, most new trials are early-stage (Phase I/II) safety and efficacy studies of such medications and delivery systems. Device Trials: A substantial portion of trials involve medical devices and implants. This includes micro-invasive glaucoma surgery (MIGS) devices, drainage stents and shunts, and laser or ultrasound systems to improve outflow. Examples might be trials of new canaloplasty implants or trabecular bypass stents, or innovative lasers (like excimer laser trabeculotomy) that create tiny drains in the trabecular meshwork. Many device trials test ways to restore the eye’s natural drainage (e.g. new iris-to-canal shunts) or to replace medications with implants. These often require surgical implantation but are generally less invasive than traditional trabeculectomy. Surgical and Procedural Trials: Some studies focus on surgical techniques rather than implants. These include comparisons of different glaucoma surgeries (for example combined cataract–glaucoma procedures versus standard surgery), or novel approaches like minimally penetrative trabeculotomies. A few are evaluating high-intensity focused ultrasound or other non-implant procedures to lower IOP. (In practice there is overlap with device trials, since many surgical trials involve an implanted device.) Digital and Diagnostic Trials: A growing niche is digital health. These trials evaluate tools like smartphone perimetry apps, home tonometry devices, AI algorithms for image screening, or telemedicine programs for remote care. For example, a recent trial is using an AI system to flag glaucoma from routine retinal photos in primary care clinics. A systematic review found 21 published studies of home-based glaucoma moni Support the show

    9분

  6. 4일 전

    April 2026 Glaucoma Trial Launches: A Global Landscape Review

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/april-2026-glaucoma-trial-launches-a-global-landscape-review Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: April 2026 Glaucoma Trial Launches: A Global Landscape Review Glaucoma is a leading cause of irreversible blindness worldwide. An estimated 76 million people had glaucoma in 2020, with that number projected to exceed 111 million by 2040 (). Most glaucoma treatments work by lowering intraocular pressure (IOP), the fluid pressure inside the eye, but new therapies aim to protect nerve cells and preserve vision. In April 2026 dozens of new glaucoma clinical trials officially began in registries around the world (ClinicalTrials.gov, EU CTR, ISRCTN, ANZCTR, CTRI, ChiCTR, WHO ICTRP). These trials span a range of intervention types – including new medications, implants and devices, surgical procedures, and digital health tools – and together paint a picture of current research priorities. New Trials by Modality The April 2026 trials can be grouped by their main intervention modality: Drug (Medication) Trials: The largest category remains medication studies. These include novel eye drops that lower IOP (for example new prostaglandin analogues or rho-kinase inhibitors) as well as systemic drugs being repurposed. Recent years have seen interest in metabolic and neuroprotective agents – for example, trials of oral diabetes drugs (GLP-1 agonists) or vitamins that may protect retinal nerve cells () (). Some trials involve sustained-release formulations (tiny implants that slowly release IOP-lowering drugs). For instance, one ongoing Phase II study is testing a tiny biodegradable implant (“TimoD”) that slowly releases the glaucoma drug timolol (). Overall, most new trials are early-stage (Phase I/II) safety and efficacy studies of such medications and delivery systems. Device Trials: A substantial portion of trials involve medical devices and implants. This includes micro-invasive glaucoma surgery (MIGS) devices, drainage stents and shunts, and laser or ultrasound systems to improve outflow. Examples might be trials of new canaloplasty implants or trabecular bypass stents, or innovative lasers (like excimer laser trabeculotomy) that create tiny drains in the trabecular meshwork. Many device trials test ways to restore the eye’s natural drainage (e.g. new iris-to-canal shunts) or to replace medications with implants. These often require surgical implantation but are generally less invasive than traditional trabeculectomy. Surgical and Procedural Trials: Some studies focus on surgical techniques rather than implants. These include comparisons of different glaucoma surgeries (for example combined cataract–glaucoma procedures versus standard surgery), or novel approaches like minimally penetrative trabeculotomies. A few are evaluating high-intensity focused ultrasound or other non-implant procedures to lower IOP. (In practice there is overlap with device trials, since many surgical trials involve an implanted device.) Digital and Diagnostic Trials: A growing niche is digital health. These trials evaluate tools like smartphone perimetry apps, home tonometry devices, AI algorithms for image screening, or telemedicine programs for remote care. For example, a recent trial is using an AI system to flag glaucoma from routine retinal photos in primary care clinics. A systematic review found 21 published studies of home-based glaucoma moni Support the show

    9분
  7. Therapeutic Mechanisms Debuting in April 2026 Glaucoma Trials

    5일 전

    Therapeutic Mechanisms Debuting in April 2026 Glaucoma Trials

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/therapeutic-mechanisms-debuting-in-april-2026-glaucoma-trials Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction Glaucoma is a chronic eye disease in which pressure buildup (intraocular pressure, or IOP) damages the optic nerve, leading to vision loss. Standard treatments focus on lowering IOP by helping fluid drain out of the eye or reducing fluid production. In 2026, several new clinical trials are testing novel approaches beyond the usual medications. These include drugs and devices that enhance outflow, suppress inflow, prevent scarring (anti-fibrotics), protect the optic nerve (neuroprotective), and improve blood flow to the nerve (vascular modulators). Each strategy has a clear laboratory rationale and often positive early human data. For example, nitric-oxide–donating prostaglandins (like NCX 470) and Rho-kinase (ROCK) inhibitors aim to widen the trabecular meshwork or veins to enhance drainage () (). Neuroprotective strategies (such as high-dose vitamin B3 or GLP-1 agonists) have shown in animal models that they can preserve retinal nerve cells even without pressure changes () (). Below we summarize each mechanism, its rationale, early evidence, and how trials measure success (e.g., IOP patterns, nerve imaging or visual fields), along with key safety issues. Outflow Enhancers What it is. These treatments aim to improve fluid drainage through the eye’s natural outflow channels (trabecular meshwork and Schlemm’s canal) or add new paths. Enhanced outflow lowers IOP without directly reducing fluid production. Examples include new eyedrop drugs and micro-invasive surgical devices. Rationale (preclinical and early data). Preclinical studies show that relaxing the trabecular meshwork or dilating outflow veins can dramatically increase fluid outflow. For instance, rock inhibitors like netarsudil relax cellular tension in the drainage tissue – in clinical trials they lowered IOP as well as timolol (a gold-standard medicine) (). Another example is QLS-111, an ATP-sensitive potassium-channel opener that dilates veins and may reduce the downstream pressure on Schlemm’s canal (). In Phase II human trials, QLS-111 added to latanoprost dropped IOP by several mmHg (). Device approaches (like suprachoroidal implants or laser trabeculoplasty) physically widen or reopen drainage channels, and early studies in animals and humans show pressure falls and improved outflow on imaging. ... Continue reading at https://visualfieldtest.com/en/therapeutic-mechanisms-debuting-in-april-2026-glaucoma-trials Support the show

    19분
  8. Gene- and Cell-Based Therapies Entering Glaucoma Trials in April 2026

    6일 전

    Gene- and Cell-Based Therapies Entering Glaucoma Trials in April 2026

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/gene-and-cell-based-therapies-entering-glaucoma-trials-in-april-2026 Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Gene- and Cell-Based Glaucoma Trials (April 2026) Emerging gene and cell therapies hold promise for glaucoma – a disease that slowly destroys the retinal ganglion cells (RGCs) (the nerve cells sending vision signals to the brain) and impedes the eye’s natural drainage of fluid (the aqueous outflow pathways). These next-generation treatments aim either to protect or regenerate RGCs (neuroprotection) or to improve outflow tissue function and lower intraocular pressure. In April 2026 several first-in-human trials will begin for such approaches. Below we summarize their main features – vectors, molecular targets, dosing plans and immune safety measures – as well as how they are delivered and controlled. We also note the ethical issues of sham controls and the required long-term safety monitoring. Gene Therapy for RGC Neuroprotection Some trials deliver genes encoding neuroprotective factors into the eye to help RGCs survive. For example, one approach uses a harmless viral vector (often an adeno-associated virus, AAV) to carry the gene for ciliary neurotrophic factor (CNTF) or brain-derived neurotrophic factor (BDNF) into retinal cells. These proteins act like growth factors to keep RGCs healthy. (Indeed, laboratory studies report that factors such as BDNF and glial cell–derived neurotrophic factor (GDNF) can greatly improve RGC survival ().) In an upcoming Phase 1 trial, for instance, patients will receive an intravitreal (into the gel of the eye) injection of an AAV vector carrying the human CNTF gene. The trial is dose-escalating: each group of patients will get a higher viral dose to find the safe and active range (typical Phase 1 design). Blood and eye exams will regularly check for immune reactions – for example, measuring if the body makes antibodies (binding or neutralizing) against the viral capsid or the new gene product (). Many ocular gene trials also use short courses of corticosteroid eye drops around the time of injection to blunt inflammation () (). Another putative gene therapy targets the neuronal degeneration process itself. For instance, trials may deliver genetic “braking” tools (like short hairpin RNA or CRISPR nucleases) to suppress harmful signals in RGCs. One example in animal studies used an AAV-delivered Cas9 gene-editing system to knock out the Wallerian degeneration pathway (which causes axons to die after injury). In mice, such treatments kept RGC axons more intact. Key points: gene therapies for RGCs typically use intravitreal or subretinal injections (small-eye surgery akin to injections for macular degeneration ()) and monitor vision function by elective tests (imaging, visual field, etc.) over time. Because gene expression is long-lasting, trials plan extended follow-up. FDA guidance, for example, calls for up to 15 years of post-treatment monitoring in gene therapy trials, focusing on late adverse events like tumor development (). A registry of treated patients may also be kept to flag any rare issues. Gene Therapy for Aqueous Outflow / IOP Lowering Other April 2026 trials aim at lowering eye pressure by improving the drainage of fluid. These target the trabecular meshwork and Schlemm’s canal (the tissues in the iridocorneal angle that normally let aqueous fluid exit the eye) Support the show

    11분
모두 보기(154개)

소개

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

정보

좋아할 만한 다른 항목